PMID- 17334957
OWN - NLM
STAT- MEDLINE
DCOM- 20070706
LR  - 20181113
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 254
IP  - 2
DP  - 2007 Feb
TI  - Patient preference in migraine therapy. A randomized, open-label, crossover 
      clinical trial of acute treatment of migraine with oral almotriptan and 
      rizatriptan.
PG  - 242-9
AB  - OBJECTIVE: To assess patient preference for almotriptan 12.5 mg vs rizatriptan 10 
      mg for the acute treatment of migraine. METHODS: Randomized, multicenter, 
      open-label, crossover trial in which triptan-naive patients treated two 
      moderate/severe migraine attacks, the first with one triptan and the second with 
      the other: 183 patients took rizatriptan followed by almotriptan and 189 treated 
      in the reverse order. Patient preference was assessed with a self-administered 
      questionnaire. RESULTS: Of those recording a preference (209), 54.5% preferred 
      almotriptan, but statistical significance was not achieved. The main reason for 
      preference for one or the other triptan was efficacy: 43% of patients preferring 
      almotriptan gave faster headache relief as the reason and 34% cited faster return 
      to normal activities. The corresponding values for rizatriptan were 47% and 38%. 
      A significantly greater proportion of those preferring almotriptan cited fewer 
      adverse events (AEs) as the reason. Almotriptan and rizatriptan were of 
      comparable efficacy and both treatments were well tolerated; 9% of patients 
      experienced AEs probably or possibly related to study medication after 
      almotriptan vs 14% after rizatriptan. Almotriptan was associated with a 
      significantly lower incidence of triptan-associated AEs in triptan-naive patients 
      (8.5% vs 18% with rizatriptan). CONCLUSION: Physicians should use information 
      from meta-analyses and preference studies like this one to aid in the selection 
      of a triptan with a high likelihood of providing rapid, sustained relief from 
      pain coupled with an absence of AEs. About 55% of patients recording a preference 
      in this trial preferred almotriptan, perhaps because of its combination of good 
      efficacy and lower incidence of triptan-associated AEs.
FAU - Diez, Fernando Iglesias
AU  - Diez FI
AD  - Department of Neurology, Hospital General Yague, Avda. Del Cid 96, 09005 Burgos, 
      Spain. iglesias@hgy.es
FAU - Straube, Andreas
AU  - Straube A
FAU - Zanchin, Giorgio
AU  - Zanchin G
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20070302
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Serotonin Receptor Agonists)
RN  - 0 (Triazoles)
RN  - 0 (Tryptamines)
RN  - 1O4XL5SN61 (almotriptan)
RN  - 51086HBW8G (rizatriptan)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Male
MH  - Meta-Analysis as Topic
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - *Patient Satisfaction/statistics & numerical data
MH  - Serotonin Receptor Agonists/*therapeutic use
MH  - Single-Blind Method
MH  - Time Factors
MH  - Triazoles/*therapeutic use
MH  - Tryptamines/*therapeutic use
EDAT- 2007/03/06 09:00
MHDA- 2007/07/07 09:00
CRDT- 2007/03/06 09:00
PHST- 2006/03/22 00:00 [received]
PHST- 2006/07/11 00:00 [accepted]
PHST- 2007/03/06 09:00 [pubmed]
PHST- 2007/07/07 09:00 [medline]
PHST- 2007/03/06 09:00 [entrez]
AID - 10.1007/s00415-006-0352-3 [doi]
PST - ppublish
SO  - J Neurol. 2007 Feb;254(2):242-9. doi: 10.1007/s00415-006-0352-3. Epub 2007 Mar 2.